Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression by Mingzhen Zhou, Ziyan Zhou, Lina Hu, Sidong Chen, Fanyan Meng, Jun Chen, Jie Shen

“…The use of anti-PD-1/PD-L1 monoclonal antibodies in HCC treatment is considerably constrained. …”
Get full text

Features of expression of immunohistochemical markers in local and generalized clear cell kidney cancer by E. M. Frantsiyants, A. N. Shevchenko, E. A. Dzhenkova, N. S. Karnaukhov, T. A. Gudtskova, A. A. Breus, E. V. Filatova, D. A. Shvyrev

“…Used system detection UltraVision Quanto Detection System (Thermo Fisher Scientific), and the Chromogen DAB. Antibodies used: E‑cadherin (EP700Y) Cell Marque, 1: 100; CD 44 (EPR1013Y) Cell Marque 1:150; Ki‑67 (SP6) Spring Bio, 1:200; P53 (DO‑7) Cell Marque, 1:200; cyclin D1 (EP12) Dako, 1:200; VEGF Termo Fisher, 1:100; Vimentin (V9) Dako, 1:150; MMP‑9 (EP100902) Epitomics, 1:100. …”
Get full text

Contextual Vulnerability Should Guide Fair Subject Selection in Xenotransplantation Clinical Trials by Gianna Strand

“…This potential subject population includes individuals with broadly reactive antibodies who are unlikely to match to a donor organ and individuals with anatomical contraindications who face prohibitive risks with standard allografts or bridging therapies.…”
Get full text